Announced details
Treatment of cardiomyopathy, old myocardial infarction and chronic heart failure resulting from these conditions
Redasemtide has already been licensed by our company to Shionogi & Co., Ltd. Osaka University is a joint applicant for this patent.
Shionogi & Co., Ltd.: Head office in Kita-ku, Osaka; Chairman, President and CEO Teshirogi Isao (手代木 功). National University Corporation Osaka University: Joint applicant for this patent. Other details: Not disclosed.
Application number: 3,051,825. Grant (publication) number: not yet determined. Validity period: Not disclosed
There will be no impact on full-year results for the fiscal year ending July 2026. Any material matter requiring disclosure will be disclosed promptly.
The company does not address Contract Value / Offering price.
Source of market size forecast: Not disclosed
| Item | Details |
|---|---|
| Names of Products / Services Covered | Regenerative Medicine Drug® Redasemtide (HMGB1 fragment peptide, development code: S-00515) |
| Counterparty | Shionogi & Co., Ltd. (privately held; no code listed) / National University Corporation Osaka University |
| Counterparty overview | Shionogi & Co., Ltd.: Head office in Kita-ku, Osaka; Chairman, President and CEO Teshirogi Isao (手代木 功). National University Corporation Osaka University: Joint applicant for this patent. Other details: Not disclosed. |
| Relationship with the Company | Redasemtide has already been licensed by our company to Shionogi & Co., Ltd. Osaka University is a joint applicant for this patent. |
| Applicable area | Treatment of cardiomyopathy, old myocardial infarction and chronic heart failure resulting from these conditions |
| Registration number and expiry date | Application number: 3,051,825. Grant (publication) number: not yet determined. Validity period: Not disclosed |
| Impact on Business Performance | There will be no impact on full-year results for the fiscal year ending July 2026. Any material matter requiring disclosure will be disclosed promptly. |
| Source | Source of market size forecast: Not disclosed |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To expand the indications for redasemtide and secure the potential to develop treatments for these diseases in North America.